Endocrine Society Tells Clinicians to Measure Obesity Treatment Beyond the Scale

The number on the scale has always been the easiest thing to put in a discharge summary. For patients on semaglutide or tirzepatide, it's also increasingly incomplete as a measure of whether treatment is actually working.

The Endocrine Society said so directly this month. A scientific statement published September 9 in Endocrine Reviews argues that clinicians and researchers need to move past percent body weight lost as the default scorecard for obesity treatment. The statement, reviewed by Healio and covered by Medical News Today, calls for treatment targets that incorporate body composition, waist circumference, cardiometabolic measures, functional status, quality of life, and whether obesity-related complications improve or go into remission.

The document doesn't dismiss the new GLP-1 drugs. It relies on them as the reason a reckoning is overdue. Semaglutide, tirzepatide, and similar agents have transformed what's clinically achievable, and as the statement notes, they're now being used not just for weight but for improving comorbidities including heart disease, sleep apnea, and kidney disease. The problem is that the pace of adoption has outrun clinicians' ability to individualize treatment, assess success beyond the scale, and manage long-term safety.

That last part carries real weight for anyone who's watched patients bounce. Patients with obesity who stop treatment after reaching their goal weight often regain it and see blood pressure, cholesterol, and blood sugar levels worsen, according to the statement as reported by Endocrine News. Researchers are now exploring whether lower doses or alternative medications can sustain the benefits without requiring indefinite full-dose therapy, but those answers aren't in yet.

Daniel J. Drucker, MD, a senior investigator at Mount Sinai Hospital in Toronto and a pioneer in GLP-1 therapy development, led the writing group. In a statement quoted by Patient Care Online, he said the document outlines "what we know, what we do not know, and what we should prioritize now that we have these powerful tools."

The Endocrine Society published the statement alongside the launch of its new Center on Obesity, a dedicated initiative to advance obesity research and care. The society also announced, per Healio, that a formal clinical practice guideline on pharmacological management of obesity is scheduled for 2027.

Melissa Shoemaker, MD, an Obesity Society spokesperson at UT Southwestern Medical Center, told Medscape she views the document as "a companion piece to existing clinical guidance," and called out the sections on BMI's limitations and the need for optimal dose adjustment as particularly useful additions.

For clinicians in practice right now, the document doesn't change what they can prescribe. What it does is push back on the instinct to declare a win or a failure based on a single number. Heart function improved. Sleep apnea resolved. The patient can walk to work again. A statement like this one asks whether we've built our outcome measures to capture any of that, and the honest answer is: not consistently.

The statement was published in Endocrine Reviews. The Endocrine Society's Center on Obesity launched the same day.

Sources cited:
- Endocrine News (Endocrine Society) (https://endocrinenews.endocrine.org/endocrine-society-scientific-statement-provides-research-roadmap-for-whats-next-in-obesity-science)
- Patient Care Online (https://www.patientcareonline.com/view/endocrine-society-calls-for-obesity-treatment-goals-beyond-weight-loss)
- Healio (https://www.healio.com/news/endocrinology/20260910/scientific-statement-to-researchers-look-at-obesity-outcomes-beyond-weight-loss)
- Medscape (https://www.medscape.com/viewarticle/endocrine-society-launches-new-initiatives-around-obesity-2026a1000xuv)
- Medical News Today (https://www.medicalnewstoday.com/articles/obesity-treatment-should-focus-on-better-health-not-weight-loss-alone)